Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586664 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT00586664 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 130 participants.
The verdict
NCT00586664, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis
Interventions
- DRUG placebo comparator
- DRUG Bepreve (bepotastine besilate ophthalmic solution) 1.5%
- DRUG Bepotastine Besilate Ophthalmic Solution 1.0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586664
The ClinicalTrials.gov registry entry for NCT00586664 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo comparator is the first listed.
NCT00586664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586664 about?
NCT00586664 is a clinical study titled "Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis". Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis
What is the current status of trial NCT00586664?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2007-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00586664?
The interventions under investigation include: placebo comparator (DRUG), Bepreve (bepotastine besilate ophthalmic solution) 1.5% (DRUG), Bepotastine Besilate Ophthalmic Solution 1.0% (DRUG).
Who is sponsoring clinical trial NCT00586664?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.